Study on Paclitaxel and Radiation Therapy for Treating Skin Angiosarcoma

Sponsor: Washington University School of Medicine

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT03921008

Provider View

This clinical trial is exploring the effectiveness of using the chemotherapy drug paclitaxel, followed by a combination of paclitaxel and radiation therapy, to treat a rare and aggressive skin cancer called cutaneous angiosarcoma before surgery.

Patient Parameters

Program Overview

Angiosarcoma is a rare and aggressive type of cancer that affects the skin and other soft tissues. It often spreads quickly, and less than half of the patients survive beyond five years. While chemotherapy and radiation have helped improve outcomes in other similar cancers, their effectiveness in treating localized angiosarcoma is not well known. This study aims to test if starting treatment with the chemotherapy drug paclitaxel, followed by a combination of paclitaxel and radiation therapy, can help control the cancer before surgery.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with cutaneous angiosarcoma confirmed by lab tests.
  • Have tumors that can be measured accurately by scans or exams.
  • Currently receiving or planning to receive weekly paclitaxel treatment for 12 weeks and able to start radiation within the first 7 weeks.
  • At least 18 years old.
  • In good overall health, able to carry out daily activities with minimal restrictions.
  • Agree to use effective birth control methods during the study.
  • Able to understand and willing to sign a consent form to participate.

Exclusion Criteria

  • Not eligible for treatment aimed at curing the cancer.
  • Have had another cancer within the last 3 years, except for certain skin cancers or cervical cancer treated with surgery.
  • Currently taking experimental drugs.
  • Have cancer that has spread to the brain or other distant parts of the body.
  • Have significant nerve damage.
  • Have allergies to paclitaxel or similar drugs.
  • Have uncontrolled health issues like infections, heart failure, or unstable heart conditions.
  • Pregnant or breastfeeding women, or women who have not had a recent negative pregnancy test.
  • HIV-positive with low immune cell counts.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.